Estetrol/drospirenone

Estetrol/drospirenone
Combination of
Estetrol Estrogen
Drospirenone Progestogen
Clinical data
Trade names Estelle (tentative)
AHFS/Drugs.com Monograph
Pregnancy
category
  • US: X (Contraindicated)
    Routes of
    administration    		 By mouth
    ATC code
    Legal status
    Legal status
    Identifiers
    ChemSpider
    • None

    Estetrol/drospirenone (E4/DRSP; tentative brand name Estelle) is a combination of estetrol, an estrogen, and drospirenone, a progestin, which is under development by Estetra S.A. as a combined oral contraceptive for the prevention of pregnancy in women.[1] It contains 15 mg estetrol and 3 mg drospirenone.[2] As of 2018, it is in phase III clinical trials for this indication.[1]

    See also

    References

    1. 1 2 http://adisinsight.springer.com/drugs/800034634
    2. ↑ https://investors.mithra.com/wp-content/uploads/2018/08/2018-08-08-Estelle-Phase-III-EU-RU-en.pdf



    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.